On February 17, 2026 ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV (Intravenously Deliverable Oncolytic Virus) platform, reported the expansion of its ongoing Phase I clinical trial of IDOV-Immune into the United States.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IDOV-Immune is ViroMissile’s leading oncolytic virus therapy candidate built on the company’s proprietary IDOV platform, the first technology designed to reliably deliver oncolytic viruses systemically and reach tumors throughout the body. The expansion follows clearance of the company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), building on the study’s initial launch in Australia and allowing leading U.S. cancer centers to begin enrolling patients with advanced solid tumors.
"Expanding our Phase I program into U.S. clinical sites marks an important step in the development of IDOV-Immune and reflects the growing momentum of our systemically deliverable oncolytic virus platform," said Nanhai George Chen, PhD, Founder and Chief Executive Officer of ViroMissile. "As we advance, our focus remains on translating years of scientific innovation into a therapeutic approach with the potential to expand what is possible for patients with advanced cancers."
The Phase I clinical trial (NCT06910657) is evaluating IDOV-Immune in adults with advanced solid tumors. The first patient was dosed at The Alfred Hospital in Melbourne, Victoria, Australia, marking the initiation of clinical evaluation. With U.S. IND acceptance, the trial will soon enroll participants at U.S. sites, including MD Anderson Cancer Center (Houston, TX), START (San Antonio, TX), and Washington University School of Medicine (St. Louis, MO).
Shah Rahimian, MD, Chief Medical Officer of ViroMissile, added, "As the Phase I study expands into U.S. sites, our priority is to generate high-quality clinical data on the safety and immune activity of IDOV-Immune as a systemically administered oncolytic therapy in patients with advanced cancers. By carefully evaluating how this therapy engages the immune system throughout the body, we aim to better understand its potential to reach metastatic disease and ultimately expand treatment options for patients with significant unmet need. These early findings will be critical in shaping the program’s future development."
(Press release, ViroMissile, FEB 17, 2026, View Source [SID1234662692])